• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

New Delhi , Dec. 12

The pharmaceutical industry wants only 62 drugs of the 354 drugs (663 formulations) in the National List of Essential Medicine (NLEM), 2003 to come under price monitoring mechanism.

This view is reflected in the report of the joint committee on Draft National Pharmaceutical Policy headed by Ms Satwant Reddy, Secretary, Department of Chemicals and Petrochemicals.

These 62 drugs are with 241 formulations. The drugs, which the industry did not want to be subjected to price control includes anti-cancer and anti-retroviral, formulations under public health programme, hospital supply products, and formulations having MRP below Rs 3 per unit. On these 62 drugs the industry has offered to roll back prices by six months from the date of the new DPCO order. It has also offered an additional 5 per cent reduction on the prices. Meanwhile, NPPA is of the view that the total number of drugs under price control should be 230 — this includes 44 drugs that are both part of the NLEM and DPCO 1995.

More Stories on : Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
SPML to invest Rs 750 cr in renewable energy

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line